During a generally quiet holiday break in biotech, Piramal Pharma has made some noise, and it starts 2022 with another big announcement.
The CDMO will invest million dollars to create a high-throughput screening facility that will enhance existing in vitro biology capabilities at its drug discovery site in Ahmedabad, India. The new extension is expected to come into service in the third quarter of this year and combine its biology services with already operational chemistry capabilities.
With the investment comes the hope of improving Piramal’s discovery services for its customers and accelerating drug discovery cycle times. It will also add new staff, hoping to test and screen 1,000 compounds per week. The platforms will be used to target G protein coupled receptors (GPCRs) and targeted kinase therapies, among others.
“Helping clients with the discovery process synergizes with our efforts to be a patient-centered CDMO,” CEO Peter DeYoung said in a statement. “With this investment, we are enhancing our discovery platform by adding new in vitro biology services to our existing capabilities, making us a more integrated partner. “
At the end of March, Piramal spent $ 106 million plus future steps for Indian peptide API maker Hemmo Pharmaceuticals. This move was seen by the company as part of a larger push into contract work in oncology and metabolic therapies, and came with a manufacturing facility in Turbhe that can produce over 30 APIs and a facility for R&D at Thane. The growth of therapies for rare diseases and orphan drugs has also increased the need for peptides, DeYoung said.
At the end of December, the Indian CDMO Yapan Bio announced that it had secured an investment from Piramal Pharma to help it improve its manufacturing branch.
Yapan provides scale-up and manufacturing services for biologics and vaccines, including RNA, DNA, recombinant vaccines, gene therapies and monoclonal antibodies. Piramal took a 27.78% stake in the company with the investment. Its goal is to help Yapan keep pace with the rapidly expanding CDMO space, in part through Piramal’s filling and finishing services.
In 2020, Piramal’s parent company consolidated all of its pharmaceutical units under one Piramal Pharma umbrella and invested $ 32 million in its 25,000 square foot API plant in Riverview, MI. He offered 20% of the pharmaceutical business in a stake sale, giving the CDMO $ 490 million in cash. It also entered into a joint venture with Allergan to manufacture the company’s eye health products.
The Indian company was recently recognized at the Confederation of Indian Industry Awards, when its Ennore and Pithampur sites were recognized as champions and star challengers.
It’s a proud moment for us as we announce that 2 of our sites have won 3 awards at the prestigious CII Champion and Challenger Awards 2021.
– Piramal Pharma (@PiramalPharma) December 27, 2021